PET心肌灌注显像及其定量分析的研究进展

孙茉茉; 李剑明; 孙茉茉; 李剑明

doi:10.3760/cma.j.issn.1673-4114.2017.06.008

[1]

Demer LL, Gould KL, Goldstein RA, et al. Assessment of coronary artery disease severity by position emission tomography. Comparison with quantitative arteriography in 193 patients[J]. Circulation, 1989, 79(4):825-835. DOI:org/10.1161/01.CIR.79.4. 825.

[2]

Tamaki N, Ruddy TD, Dekamp R, et al. Myocardial perfusion[M]//Wahl RL, Buchanan JW. Principles and Practice of Positron Emission Tomography. Philadelphia:Lippincott, Williams & Wilkins, 2002:320-333.

[3]

Sampson UK, Dorbala S, Limaye A, et al. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease[J]. J Am Coll Cardiol, 2007, 49(10):1052-1058. DOI:10.1016/j.jacc.2006.12.015.

[4]

J Epstein N, Benelfassi A, SB Beanlands R, et al. An ⁸²Rb infusion system for quantitative perfusion imaging with 3D PET[J]. Appl RadiatIsot, 2004, 60(6):921-927. DOI:10.1016/j.apradiso.2004. 02.002.

[5]

Anagnostopoulos C, Almonacid A, El Fakhri G, et al. Quantitative relationship between coronary vasodilator reserve assessed by ⁸²Rb PET imaging and coronary artery stenosis severity[J]. Eur J Nucl Med Mol Imaging, 2008, 35(9):1593-1601. DOI:10.1007/s00259-008-0793-2.

[6]

Uren NG, Melin JA, De Bruyne B, et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis[J]. N Engl J Med, 1994, 330(25):1782-1788. DOI:10.1056/NEJM199406233302503.

[7]

Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease[J]. Circulation, 1995, 91(7):1944-1951. DOI:org/10.1161/01.CIR.91.7.1944.

[8]

Lubberink M, Harms HJ, Halbmeijer R, el al. Low-Dose Quantitative Myocardial Blood Flow Imaging Using ¹⁵O-Water and PET Without Attenuation Correction[J]. J NuclMed, 2010, 51(4):575-580. DOI:10.2967/jnumed.109.070748.

[9]

李帅, 李剑明. ¹⁸F标记新型正电子心肌灌注显像剂的研究进展[J].中国医学影像技术, 2014, 30(6):926-929.Li.
Li S, Li JM. Progresses of new myocardial perfusion imaging agents labeled with ¹⁸F[J]. Chin J Med Imaging Technol, 2014, 30(6):926-929.

[10]

Berman DS, Germano G, Slomka PJ. Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz ¹⁸F[J]. J Nucl Cardiol, 2012, 19 Suppl 1:S38-45. DOI:10.1007/s12350-011-9487-4.

[11]

彭程, 赵祚全, 陈淑婷, 等. ¹⁸F标记的新型鏻正阳离子PET心肌灌注显像剂的制备及生物性能评价[J].同位素, 2014, 27(4):223-229. DOI:10.7538/tws.2014.27.04.0223.
Peng C, Zhao ZQ, Chen ST, et al. Preparation and biological evaluation of novel ¹⁸F-labeled phosphonuimcation for myocardial perfusion imaging with PET[J]. J Isotopes, 2014, 27(4):223-229. doi: 10.7538/tws.2014.27.04.0223

[12]

王道宇, 牟甜甜, 赵祚全, 等.新型¹⁸F标记心肌灌注显像剂的PET显像实验研究[J].中国医学装备, 2015, 12(6):50-53. DOI:10.3969/J.ISSN.1672-8270.2015.06.016.
Wang DY, Mou TT, Zhao ZQ, et al. The preliminary experimental study of a novel ¹⁸F-labeled myocardial perfusion imaging agent for PET imaging[J]. China Med Equipment, 2015, 12(6):50-53. doi: 10.3969/J.ISSN.1672-8270.2015.06.016

[13]

汪娇, 李剑明. PET/CT正电子心肌灌注显像剂的研究进展[J].中国医学影像学杂志, 2014, 138(11):877-880. DOI:10.3969/j.issn.1005-5185.2014.11.021.
Wang J, Li JM. Research progress of PET/CT myocardial perfusion imaging agent[J]. Chin J Med Imaging, 2014, 138(11):877-880. doi: 10.3969/j.issn.1005-5185.2014.11.021

[14]

Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02:a novel PET myocardial perfusion imaging agent[J]. J Nucl Cardiol, 2007, 14(6):789-798. DOI:10.1016/j.nuclcard.2007.07.008.

[15]

Maddahi J, Czernin J, Lazewatsky J, et al. Phase Ⅰ, first-in-human study of BMS747158, a novel ¹⁸F-labeled tracer for myocardial perfusion PET:dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest[J]. J Nucl Med, 2011, 52(9):1490-1498. DOI:10.2967/jnumed.111.092528.

[16]

Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction[J]. N Engl J Med, 1994, 331(4):222-227. DOI:10.1056/NEJM199407283310402.

[17]

Parkash R, Dekemp RA, Ruddy TD, et al. Potential utility of Rubidium 82 PET quantification in patients with 3-vessel coronary artery disease[J]. J NuclCardiol, 2004, 11(4):440-449. DOI:10.1016/j. nuclcard.2004.04.005.

[18]

Yoshinaga K, Katoh C, Manabe O, et al. Incremental diagnostic value of regional myocardial blood flow quantifcation over relative perfusion imaging with generator-produced rubidium-82 PET[J]. Circ J, 2011, 75(11):2628-2634. DOI:org/10.1253/circj.CJ-11-0502.

[19]

Fiechter M, Ghadri JR, Gebhard C, et al. Diagnostic value of ¹³N-ammonia myocardial perfusion PET:added value of myocardial flow reserve[J]. J Nucl Med, 2012, 53(8):1230-1234. DOI:10.2967/jnumed.111.101840.

[20]

Yoshinaga K, Tomiyama Y, Tamaki N, et al. Myocardial blood flow quantification using positron-emission tomography:analysis and practicein the clinical setting[J]. Circ J, 2013, 77(7):1662-1671. DOI:10.1253/circj.CJ-13-0235.

[21]

田丛娜, 魏红星, 张晓丽. PET心肌灌注显像测定心肌血流量及冠状动脉血流储备的研究进展[J].国际放射医学核医学杂志, 2012, 36(5):274-279. DOI:10.3760/cnla.j.issn.1673-4114. 2012. 05.004.
Tian CN, Wei HX, Zhang XL. Progress of myocardial blood flow and coronary flow reserve measurement using PET myocardial perfusion imaging[J]. Int J Radiat Med Nucl Med, 2012, 36(5):274-279. doi: 10.3760/cnla.j.issn.1673-4114.2012.05.004

[22]

Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization:A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American H eart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2012, 59(22):1995-2027. DOI:10.1016/j.jacc.2012. 03.003.

[23]

Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update:a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography[J]. J Am Coll Cardiol, 2012, 59(9):857-881. DOI:10.1016/j.jacc.2011.12.001.

[24]

Di Carli MF, Dorbala S. Integrated PET/CT for cardiol imaging[J]. Q J Nucl Med Mol Imaging, 2006, 50(1):44-52.

[25]

Beanlands RS, Dekemp RA, Smith S, et al. F-18-Fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function[J]. Am J Cardiol, 1997, 79(8):1092-1095. DOI:10.1016/S0002-9149(97)00054-4.

[26]

Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently ofluminal angiographic severity and modifies the effectof early revascularization[J]. Circulation, 2015, 131(1):19-27. DOI:10.1161/CIRCULATIONAHA.114.011939.

[27]

Dorbala S, Di Carli MF. Cardiac PET perfusion:prognosis, risk stratification, and clinical management[J]. Semin Nucl Med, 2014, 44(5):344-357. DOI:10.1053/j.semnuclmed.2014.05.003.

[28]

Dorbala S, Di Carli MF, Beanlands RS, et al. Prognostic value of stress myocardial perfusion positron emission tomography:results from a multicenter observational registry[J]. J Am CollCardiol, 2013, 61(2):176-184. DOI:10.1016/j.jacc.2012.09.043.

[29]

Dorbala S, Hachamovitch R, Curillova Z, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF[J]. JACC Cardiovasc Imaging, 2009, 2(7):846-854. DOI:10.1016/j.jcmg.2009.04.009.

[30]

Farhad H, Dunet V, Bachelard K, et al. Added prognostic value of myocardial blood flow quantitation in rubidium-82 positron emission tomography imaging[J]. Eur Heart J Cardiovasc Imaging, 2013, 14(12):1203-1210. DOI:10.1093/ehjci/jet068.

[31]

Valenta I, Quercioli A, Vincenti G, et al. Structuralepicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT[J]. J Nucl Cardiol, 2010, 17(6):1023-1033. DOI:10.1007/s12350-010-9272-9.

[32]

De Bruyne B, Hersbach F, Pijls NH, et al. Abnormalepicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography[J]. Circulation, 2001, 104(20):2401-2406. doi: 10.1161/hc4501.099316

[33]

Valenta I, Wahl RL, Schindler TH. Longitudinal myocardial blood flow gradient and CAD detection[J]. Curr Cardiol Rep, 2015, 17(1):550. DOI:10.1007/s11886-014-0550-z.

[34]

Valenta I, Quercioli A, Schindler TH, et al. Diagnostic value of PET-Measured longitudinal flow gradient for the identification of coronary artery disease[J]. JACC Cardiovasc Imaging, 2014, 7(4):387-396. DOI:10.1016/j.jcmg.2014.01.001.

[35]

Lanza GA, Crea F. Primary coronary microvascular dysfunction:clinical presentation, pathophysiology, and management[J]. Circulation, 2010, 121(21):2317-2325. DOI:10.1161/CIRCULATI ONAHA.109.900191.

[36]

Leung DY, Leung M. Non-invasive/invasive imaging:significance and assessment of coronary microvasculardysfunction[J]. Heart, 2011, 97(7):587-595. DOI:10.1136/hrt.2009.183327.

[37]

Cecchi F, Olivotto I, Gistri R, et al. Coronarymicrovascular dysfunction and prognosis in hypertrophic cardiomyopathy[J]. N Engl J Med, 2003, 349(11):1027-1035. DOI:10.1056/NEJMoa025050.

[38]

Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2006, 47(5):1043-1048. DOI:10.1016/j.jacc.2005.10.050.

[39]

Castagnoli H, Ferrantini C, Coppini R, et al. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy:a 2016 reappraisal[J]. Eur J Nucl Med Mol Imaging, 2016, 43(13):2413-2422. DOI:10.1007/s00259-016-3465-7.